Most Read Articles
22 Nov 2020
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

4 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 2 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.

Dehydroepiandrosterone boosts QoL of premenopausal RA patients

21 Oct 2020

Dehydroepiandrosterone (DHEA) supplementation confers benefits for quality of life (QoL) but not for disease activity relative to placebo in premenopausal women with rheumatoid arthritis (RA), a study has found.

Forty-six patients were randomized to receive 50 mg/day DHEA (n=23) or placebo (n=23) for 12 weeks. Those in the active treatment group were slightly younger (mean age, 34.8 vs 38.4 years), had shorter disease duration (mean, 4.67 vs 6.91 months), slightly lower DHEA levels (mean, 3.78 vs 4.47 µg/mL), and lower prednisolone use (mean, 3.5 vs 4.6 mg/day), although the differences were not significant.

At the end of treatment, the DHEA group showed greater improvements in QoL (measured using the World Health Organization Quality of Life Brief version questionnaire; p=0.025) and environment health (p=0.001) than the placebo group.

In an analysis controlled for age and disease duration, DHEA was still associated with more favourable changes in QoL (p=0.01), as well as in psychological (p=0.02) and physical health (p=0.03).

Disease Activity Score of 28 joints score decreased with DHEA and placebo, but there was no significant between-group difference observed (p=0.88). Meanwhile, there was a trend toward reduced erythrocyte sedimentation rate in the DHEA group (p=0.06).

Adverse events were minor and occurred with similar frequency in the DHEA and placebo groups. These included epigastric pain (4 percent and 13 percent), menstruation disorder (9 percent in both), headache (4 percent vs 0 percent), spotting (0 percent vs 9 percent), hair loss (0 percent vs 13 percent), and aggressive behaviour (17 percent vs 13 percent).

DHEA is said to influence brain function and some features of human emotions and behaviour, with positive effects on memory and mood.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Nov 2020
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

4 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 2 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.